Imatinib as a Treatment Option for Systemic Non-Langerhans Cell Histiocytoses

This publication has 14 references indexed in Scilit:

• Extranodal Rosai-Dorfman disease of the kidney and coexistent poorly differentiated prostatic adenocarcinoma.
  Archives of Pathology & Laboratory Medicine, 2006
• Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia
  Leukemia, 2006
• The development and application of imatinib
  Expert Opinion on Drug Safety, 2005
• Uncommon histiocytic disorders: The non‐Langerhans cell histiocytoses
  Pediatric Blood & Cancer, 2004
• PET imaging of Rosai-Dorfman disease: correlation with histopathology and ex-vivo beta-imaging
  Archives of Dermatological Research, 2003
• Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases
  Leukemia, 2002
• Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
  The Lancet, 2001
• Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR
  Leukemia, 1999
• Immunohistochemical comparison of cutaneous histiocytoses and related skin disorders: Diagnostic and histogenetic relevance of MS‐1 high molecular weight protein expression
  The Journal of Pathology, 1993
• Minimal Residual Disease after Bone Marrow Transplant for Chronic Myeloid Leukaemia Detected by the Polymerase Chain Reaction
  Leukemia & Lymphoma, 1993